ImmunoGen, Inc. (IMGN), a biotechnology company developing targeted anticancer therapeutics using its Targeted Antibody Payload technology, announced preclinical data for its EGFR-targeting ADC, IMGN289, which would be presented at the American Association for Cancer Research Annual Meeting 2013 in Washington, DC. ImmunoGen developed IMGN289 to treat EGFR-overexpressing cancers, consisting of many cases of squamous cell carcinoma of the head and neck or SCCHN and non-small cell lung cancer or NSCLC, and expects to begin clinical testing of the compound later this year.
IMGN289 contains an EGFR-binding antibody that can achieve significant inhibition of EGFR-signaling, an important mechanism of action for EGFR-overexpressing cancers being fueled by EGFR. In studies reported today, the antibody in IMGN289 was shown to provide potency comparable to or better than cetuximab in preclinical models of SCCHN and NSCLC.
According to ImmunoGen, IMGN289 is on track to become the company's fourth wholly owned clinical-stage compound. The company is preparing to submit the IMGN289 IND in mid-2013 and to begin IMGN289 clinical testing later this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.